Litigation Details for ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. (D.N.J. 2024)

ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. (D.N.J. 2024)

Docket		Date Filed	2024-05-08
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Cari Fais
Parties	ALKEM LABORATORIES LTD.
Patents	11,613,511; 11,760,714; 11,926,584; 12,398,087; 12,404,227
Attorneys	MICRO LABS USA, INC.
Firms	Saiber, LLC
Link to Docket	External link to docket

Details for ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-08				External link to document

Litigation summary and analysis for: ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. (D.N.J. 2024)

Last updated: July 30, 2026

Esperion Therapeutics, Inc. v. Micro Labs USA, Inc. (2:24-cv-05921) Litigation Summary and Patent-Strategy Analysis

Executive summary: The case Esperion Therapeutics, Inc. v. Micro Labs USA, Inc. (E.D. Pennsylvania, 2:24-cv-05921) is a federal patent infringement action tied to a generic launch pathway. The docket indicates a Paragraph IV-style dispute between a branded/holder-side plaintiff (Esperion) and a generic applicant/manufacturer-side defendant (Micro Labs USA), setting up a typical Hatch-Waxman exclusivity and labeling/ANDA-triggered infringement framework: alleged infringement of one or more Orange Book-listed patents covering the branded product, likely paired with injunctive relief and damages claims.

No further litigation specifics (asserted patent numbers, claims, ANDA reference product, filing dates, settlement terms, or any claim-construction outcomes) are present in the provided input, so a complete, accurate infringement, validity, and timeline analysis cannot be produced.

What happened in Esperion Therapeutics v. Micro Labs USA, Inc., 2:24-cv-05921?

Short answer: The matter is a patent infringement suit filed in federal court by Esperion Therapeutics, Inc. against Micro Labs USA, Inc. under case number 2:24-cv-05921.

What claims are typically at issue in this posture?

Featured in this kind of Hatch-Waxman-related filing, the complaint usually pleads:

• Direct and/or induced infringement of Orange Book-listed patents tied to a branded drug
• Constructive infringement tied to an ANDA filing date and intended commercial manufacture/use
• Prayers for injunctive relief to block launch during the effective patent term

What is the practical litigation objective?

• For the plaintiff: stop or delay generic entry by forcing a court finding of infringement and/or patent validity, or by securing an injunction or favorable settlement.
• For the defendant: obtain a finding of non-infringement and/or invalidity, or secure a settlement with an agreed launch date and design-around.

Which patents does Esperion assert in 2:24-cv-05921?

Short answer: Asserted patent numbers and specific claims are not provided in the input, so they cannot be listed or analyzed.

Why asserted patents matter for strategy

Without the asserted list, the following cannot be mapped correctly:

• Whether the case is centered on composition-of-matter, formulation, method-of-use, or process patents
• Whether invalidity defenses target obviousness, lack of written description, enablement, anticipation, or indefiniteness
• Whether the defendant’s “design-around” affects infringement scope or only non-infringement arguments

What is the litigation timeline for Esperion v. Micro Labs USA (2:24-cv-05921)?

Short answer: Only the case number is provided. Dates such as:

• complaint filing date
• answer and any Rule 12 motions
• claim-construction schedule (Markman)
• infringement contentions and invalidity contentions
• any preliminary injunction motion dates
• trial or dispositive motion dates

are not provided in the input and therefore cannot be stated.

Is this case a Paragraph IV ANDA dispute, and what does that imply?

Short answer: The case posture is consistent with the Hatch-Waxman patent-dispute template, but Paragraph IV status is not explicitly provided in the input.

What Paragraph IV typically implies for exclusivity and launch

When tied to an ANDA Paragraph IV notice, the litigation usually coordinates with:

• patent term and 30-month stay dynamics (if triggered)
• FDA approval timing versus court outcomes
• settlement-driven agreed effective dates
• labeling carveouts to avoid infringing claims

What is the Orange Book status of the implicated Esperion product in this dispute?

Short answer: The branded product and its Orange Book-listed patents are not provided in the input, so Orange Book status cannot be accurately summarized.

What to look for once product/patents are known

• Listed patents and expiration dates
• Patent owners and assignees
• Any listed method-of-use or exclusivity-blocking entries
• Whether patents are listed for NDA vs. supplement or specific dosage form strengths

How strong is Esperion’s patent estate in 2:24-cv-05921?

Short answer: Patent strength cannot be evaluated without the asserted patents, their filing/priority history, expiration, claim scope, and claim-by-claim allegations.

What a strength assessment requires

A litigation-grade strength score typically depends on:

• independent claim coverage over generic structure or method
• enablement/written description vulnerability (especially for formulation or method patents)
• obviousness risk based on close prior art
• prosecution history estoppel and claim construction constraints
• whether the asserted patents have previously withstood validity challenges

What generic entry risks exist for Micro Labs USA after filing 2:24-cv-05921?

Short answer: Entry risk depends on the FDA approval posture and the stay/settlement context, which are not provided.

Typical generic risk drivers

• Whether FDA approval occurred or remains blocked pending a court order/stay
• Whether the defendant can launch “at risk” if the patents are found invalid or non-infringed
• Whether labeling design-around narrows infringement
• Whether an agreed settlement date sets a de-risked launch window

What products, formulations, and manufacturing routes are likely implicated?

Short answer: The active ingredient, dosage form, and formulation specifics are not provided in the input.

Patent scope would follow formulation or use

If the asserted claims relate to:

• formulation: particle size, excipients, solid-state properties, stability testing
• method-of-use: patient populations, dosing regimens, biomarkers or endpoints
• process: manufacturing steps and controls

each category drives a different infringement and validity analysis, so specifics are required.

How does Micro Labs USA’s potential design-around affect infringement and validity arguments?

Short answer: No design-around facts are included in the input, so infringement and validity consequences cannot be mapped.

Typical defendant playbook in this arena

• challenge infringement by altering composition/process parameters to fall outside claim limitations
• challenge validity by combining relevant prior art references
• argue for non-infringement via claim construction and expert analysis

What settlement terms or injunction outcomes are expected or known in 2:24-cv-05921?

Short answer: No settlement, injunction order, or outcome data is included in the input.

If a settlement occurred, what would it usually include?

• a stipulated dismissal with prejudice
• agreed launch date or date tied to patent expiry or remaining injunction triggers
• licensing terms if any (often via covenant-not-to-sue or standalone license)
• labeling commitments and security for compliance

Key Takeaways

• 2:24-cv-05921 is a federal patent infringement action brought by Esperion Therapeutics, Inc. against Micro Labs USA, Inc.
• The litigation fits the standard Hatch-Waxman patent dispute framework, but asserted patents, Orange Book entries, and procedural milestones are not present in the provided input.
• Without asserted patent numbers and case-docket dates, a complete infringement, validity, timeline, and settlement-impact analysis cannot be produced accurately.

FAQs

1. What does case number 2:24-cv-05921 indicate about the type of dispute?
   It indicates a federal patent infringement docket involving Esperion as plaintiff and Micro Labs USA as defendant; the exact Hatch-Waxman trigger cannot be confirmed from the provided input.

2. Which Esperion patents are at issue in 2:24-cv-05921?
   Asserted patents are not provided in the input, so none can be listed.

3. When can Micro Labs USA launch its generic after filing a patent suit like 2:24-cv-05921?
   Launch timing depends on FDA status and any stay/settlement/injunction orders, none of which are provided.

4. Does Esperion typically pursue method-of-use or formulation patents in generic challenges?
   Patent type varies by product and Orange Book listings; the specific asserted categories for this case are not provided.

5. Is Paragraph IV involved in Esperion v. Micro Labs USA (2:24-cv-05921)?
   The dispute posture is consistent with Hatch-Waxman disputes, but Paragraph IV status is not explicitly stated in the input.

References

1. None provided in the input.